RESUMEN
BACKGROUND: Sickle cell anemia (SCA) patients exhibit sub-phenotypes associated to hemolysis and vaso-occlusion. The disease has a chronic inflammatory nature that has been also associated to alterations in the lipid profile. This study aims to analyze hematological and biochemical parameters to provide knowledge about the SCA sub-phenotypes previously described and suggest a dyslipidemic sub-phenotype. METHODS: A cross-sectional study was conducted from 2013 to 2014, and 99 SCA patients in steady state were enrolled. We assessed correlations and associations with hematological and biochemical data and investigated the co-inheritance of -α3.7Kb-thalassemia (-α3.7Kb-thal). Correlation analyses were performed using Spearman and Pearson coefficient. The median of quantitative variables between two groups was compared using t-test and Mann-Whitney. P-values <0.05 were considered statistically significant. RESULTS: We found significant association of high lactate dehydrogenase levels with decreased red blood cell count and hematocrit as well as high levels of total and indirect bilirubin. SCA patients with low nitric oxide metabolites had high total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol and reduced very low-density cholesterol, triglycerides, direct bilirubin level and reticulocyte counts. In SCA patients with high-density lipoprotein cholesterol greater than 40 mg/dL, we observed increased red blood cell count, hemoglobin, hematocrit, and fetal hemoglobin and decreased nitric oxide metabolites levels. The presence of -α3.7Kb-thal was associated with high red blood cell count and low mean corpuscular volume, mean corpuscular hemoglobin, platelet count and total and indirect bilirubin levels. CONCLUSIONS: Our results provide additional information about the association between biomarkers and co-inheritance of -α3.7Kb-thal in SCA, and suggest the role of dyslipidemia and nitric oxide metabolites in the characterization of this sub-phenotype.
Asunto(s)
Anemia de Células Falciformes/fisiopatología , Dislipidemias/etiología , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/genética , Bilirrubina/sangre , Biomarcadores/sangre , Brasil , Estudios Transversales , Recuento de Eritrocitos , Índices de Eritrocitos , Eliminación de Gen , Hematócrito , Hemoglobina H/genética , Heterocigoto , Homocigoto , Humanos , L-Lactato Deshidrogenasa/sangre , Lípidos/sangre , Óxido Nítrico/sangre , Recuento de Plaquetas , Talasemia alfa/complicaciones , Talasemia alfa/genéticaRESUMEN
To date, hydroxyurea is the only effective and safe drug that significantly reduces morbidity and mortality of individuals with Sickle cell disease. Twenty years of real-life experience has demonstrated that hydroxyurea reduces pain attacks, vaso-occlusive events, including acute chest syndrome, the number and duration of hospitalizations and the need for transfusion. The therapeutic success of hydroxyurea is directly linked to access to the drug, the dose used and adherence to treatment which, in part, is correlated to the availability of hydroxyurea. This consensus aims to reduce the number of mandatory exams needed to access the drug, prioritizing the requesting physician's report, without affecting patient safety.
RESUMEN
Introduction: The clarification of etiopathology, the improvement of chemotherapy regimens and their risk stratifications, and the improvement in treatment support have increased the survival of children and adolescents affected by Acute Lymphoblastic Leukemia (ALL) past few years. This study aimed to estimate overall survival (OS) and event-free survival (EFS) in an onco-hematology treatment center in Brazil, reports the main clinical-laboratory characteristics of patients at diagnosis, verify the frequency of treatment-related adverse effects and the main causes of death. Material and methods: Retrospective analysis involving patients diagnosed with ALL, treated with the protocol of the Brazilian Group for Treatment of Leukemias in Childhood (GBTLI), between 2010 and 2020 was carried out; the outcomes (relapse, deaths, development of new neoplasms) were analyzed SPSS® software was used for the statistical analyses, and the p-value was considered significant when less than 0.05 for all analyses. Results: 109 patients were included in the study; the median age was 5 years, with a slight predominance of males. Sixty-six patients were classified as high-risk (HR) group and 43 patients were classified as low-risk (LR) group. After 5 years of diagnosis, the OS was 71.5%, and the EFS was 65%. No statistical difference was found between the HR and LR groups for OS and EFS, while leukocyte counts were statistically associated with the outcome of death (p = 0.028). Among the patients, 28 (25.6%) died due to infection accounting 46.4% of death causes. Among the 34 patients with unfavorable outcomes (death and/or relapse), 32 had no research for the minimal residual disease at the end of remission induction, and 25 were not investigated for the presence of chromosomal abnormalities. The most reported complications and treatment-related adverse effects were increased liver transaminases (85.9%), airway infection (79.4%), oral mucositis (67.2%), febrile neutropenia (64.4%), and diarrhea (36.4%). Conclusions: The rates of OS and EFS obtained in this cohort are similar to those obtained in the few previous similar studies in Brazil and lower than those carried out in developed countries. The unavailability of prognostic tests may have hindered risk stratification and influenced the results obtained.
RESUMEN
Sickle cell disease (SCD) is characterized by the presence of the variant S hemoglobin (HbS). The homozygous genotype (HbSS) is sickle cell anemia (SCA), while the double heterozygous of HbS and HbC (HbSC) is defined as SC hemoglobinopathy. The pathophysiology is based on chronic hemolysis, inflammation, endothelial dysfunction, and vaso-occlusion, which results in vasculopathy and serious clinical manifestations. Sickle leg ulcers (SLUs) are cutaneous lesions around the malleoli frequent in 20% of Brazilian patients with SCD. SLUs present a variable clinical and laboratory pattern modulated by several characteristics that are not fully understood. Hence, this study aimed to investigate laboratory biomarkers and genetic and clinical parameters associated with the development of SLUs. This descriptive cross-sectional study included 69 SCD patients, 52 without SLU (SLU-) and 17 with active or previous SLU history (SLU+). The results showed a higher incidence of SLU in SCA patients and there was no observed association of α-3.7 Kb thalassemia in SLU occurrence. Alterations in NO metabolism and hemolysis were associated with clinical evolution and severity of SLU, in addition to hemolysis modulating the etiology and recurrence of SLU. Our multifactorial analyses demonstrate and extend the role of hemolysis driving the pathophysiological mechanism of SLU.
Asunto(s)
Anemia de Células Falciformes , Cromosomas Humanos Par 11/genética , Cromosomas Humanos Par 2/genética , Hemoglobina Fetal , Hidroxiurea/administración & dosificación , Adolescente , Adulto , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/tratamiento farmacológico , Anemia de Células Falciformes/genética , Niño , Preescolar , Femenino , Hemoglobina Fetal/genética , Hemoglobina Fetal/metabolismo , Estudio de Asociación del Genoma Completo , Humanos , MasculinoRESUMEN
Sickle leg ulcers (SLU) are malleoli lesions with exuberant hemolytic pathophysiology. The microRNAs are potential genetic biomarkers for several pathologies. Thereby, we aimed to assess the expression of circulating miR-199a-5p, miR-144, and miR-126 in association with hemolytic biomarkers in SLU. This cross-sectional study included 69 patients with sickle cell disease, 52 patients without SLU (SLU-) and 17 patients with active SLU or previous history (SLU+). The results demonstrated elevated expression of circulating miR-199a-5p and miR-144 in SLU+ patients while miR-126 expression was reduced. Circulating miR-199a-5p and miR-144 were associated with hemolytic biomarkers such as LDH, indirect bilirubin, AST, GGT, iron, ferritin, RBC, hemoglobin, and NOm, in addition to association with impaired clinical profile of SLU. Furthermore, in silico analyses indicated interactions of miR-199a-5p with HIF1A, Ets-1, and TGFB2 genes, which are associated with vasculopathy and reduced NO. In contrast, miR-126 was associated with an attenuating clinical profile of SLU, in addition to not characterizing hemolysis. In summary, this study demonstrates, for the first time, that hemolytic mechanism in SLU can be characterized by circulating miR-199a-5p and miR-144. The circulating miR-126 may play a protective role in SLU. Thus, these microRNAs can support to establish prognosis and therapeutic strategy in SLU.
Asunto(s)
Anemia de Células Falciformes , Úlcera de la Pierna , MicroARNs , Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/genética , Biomarcadores , Estudios Transversales , Hemólisis , Humanos , Úlcera de la Pierna/complicaciones , Úlcera de la Pierna/genética , MicroARNs/genética , MicroARNs/metabolismoRESUMEN
Therapy-related acute myeloid leukemia (t-AML) following treatment with topoisomerase-II inhibitors has been increasingly reported. These compounds (e.g. etoposide) promote DNA damage and are associated with KMT2A rearrangements. They are widely used as first-line treatment in hemophagocytic lymphohistiocytosis (HLH). Here we describe a newborn who developed t-AML after HLH treatment. We provide detailed clinical, cytogenetic, and molecular characteristics of this patient, including the identification of a novel gene fusion - KMT2A-SNX9 - in t-AML. Considering the dismal outcome of this case, we discuss the side-effects of etoposide administration during HLH treatment in infants.
Asunto(s)
Diploidia , Cariotipo , Leucemia Mieloide Aguda/inducido químicamente , Leucemia Mieloide Aguda/genética , Linfohistiocitosis Hemofagocítica/tratamiento farmacológico , Proteínas de Fusión Oncogénica/genética , Secuencia de Bases , Niño , Resultado Fatal , Humanos , Lactante , Recién Nacido , MasculinoRESUMEN
Abstract To date, hydroxyurea is the only effective and safe drug that significantly reduces morbidity and mortality of individuals with Sickle cell disease. Twenty years of real-life experience has demonstrated that hydroxyurea reduces pain attacks, vaso-occlusive events, including acute chest syndrome, the number and duration of hospitalizations and the need for transfusion. The therapeutic success of hydroxyurea is directly linked to access to the drug, the dose used and adherence to treatment which, in part, is correlated to the availability of hydroxyurea. This consensus aims to reduce the number of mandatory exams needed to access the drug, prioritizing the requesting physician's report, without affecting patient safety.
RESUMEN
The authors present a proposal of a partnership between the Sociedade Brasileira de Oncologia Pediátrica (SOBOPE) and the International Society of Pediatric Oncology (SIOP) to promote the standardization and improvement of nutritional care of kids under cancer treatment in Brazil. The results of the first meeting in Brazil as well as plans for future meetings are described.
RESUMEN
BACKGROUND: In this study, we evaluate the association of different clinical profiles, laboratory and genetic biomarkers in patients with sickle cell anemia (SCA) and hemoglobin SC disease (HbSC) in attempt to characterize the sickle cell disease (SCD) genotypes. METHODS: We conducted a cross-sectional study from 2013 to 2014 in 200 SCD individuals (141 with SCA; 59 with HbSC) and analyzed demographic data to characterize the study population. In addition, we determined the association of hematological, biochemical and genetic markers including the ßS-globin gene haplotypes and the 3.7 Kb deletion of α-thalassemia (-α3.7Kb-thal), as well as the occurrence of clinical events in both SCD genotypes. RESULTS: Laboratory parameters showed a hemolytic profile associated with endothelial dysfunction in SCA individuals; however, the HbSC genotype was more associated with increased blood viscosity and inflammatory conditions. The BEN haplotype was the most frequently observed and was associated with elevated fetal hemoglobin (HbF) and low S hemoglobin (HbS). The -α3.7Kb-thal prevalence was 0.09 (9%), and it was associated with elevated hemoglobin and hematocrit concentrations. Clinical events were more frequent in SCA patients. CONCLUSIONS: Our data emphasize the differences between SCA and HbSC patients based on laboratory parameters and the clinical and genetic profile of both genotypes.
RESUMEN
BACKGROUND: Acute myeloid leukemia presenting the MYST3-CREBBP fusion gene is a rare subgroup associated with hemophagocytosis in early infancy and monocytic differentiation. The aim of this study was to define the relevant molecular cytogenetic characteristics of a unique series of early infancy acute myeloid leukemia cases (≤24months old), based on the presence of hemophagocytosis by blast cells at diagnosis. METHODS: A series of 266 infant cases of acute myeloid leukemia was the reference cohort for the present analysis. Acute myeloid leukemia cases with hemophagocytosis by blast cells were reviewed to investigate the presence of the MYST3-CREBBP fusion gene by fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction. RESULTS: Eleven cases with hemophagocytosis were identified with hemophagocytic lymphohistiocytosis being ruled out. Six cases were classified as myelomonocytic leukemia, three as AML-M7 and two as AML-M2. In five cases, the presence of the MYST3-CREBBP fusion gene identified by molecular cytogenetics was confirmed by fluorescence in situ hybridization. All patients received treatment according to the Berlin-Frankfürt-Münster acute myeloid leukemia protocols and only one out of the five patients with the MYST3-CREBBP fusion gene is still alive. CONCLUSIONS: Our findings demonstrate that the presence of hemophagocytosis in acute myeloid leukemia was not exclusively associated to the MYST3-CREBBP fusion gene. Improvements in molecular cytogenetics may help to elucidate more complex chromosomal rearrangements in infants with acute myeloid leukemia and hemophagocytosis.
RESUMEN
UNLABELLED: A Severe Aplastic Anemia is a rare disease that happens in the entire world. Because the rarity, it is difficult to characterize the features of the patients that have this disease, and to find their possible etiological factors. PURPOSE: To report all cases of severe aplastic anemia in young people who were attended in the hospital and characterize some variables like age, sex, geographic area of residence, etiologies and socioeconomic status. METHODS: It was done a descriptive analyze of all pediatric patient's features (below 18 years) who came to the hospital in 1979-1993 with severe aplastic anemia based on the classification proposed for Camitta et al. The data were obtained from the hospital records in 134 children, and the investigator in 79 families performed interviews. RESULTS: The age ranged from 2-18 years (mean 10.89 years). The male to female ratio was 64:70. Most of the patients came from urban zone of south Brazil. We did not identify any etiologic agents in 34% of the cases. Prior exposure to the agricultural pesticides and benzene derivative was the most common etiologic factors that were related. The household income of 83.5% of the families was < $ 65 U.S./capita, and 70.9% of the patient's mother did not finish the primary school CONCLUSION. In this group, severe aplastic anemia is more frequent in 11 years old girls. Most of them are the in urban zone of south Brazil, with low socioeconomic status, and related prior exposure agricultural pesticides and benzene derivative.
Asunto(s)
Anemia Aplásica/epidemiología , Adolescente , Anemia Aplásica/etiología , Anemia Aplásica/terapia , Brasil/epidemiología , Niño , Preescolar , Demografía , Femenino , Humanos , Masculino , Plaguicidas/efectos adversos , Población Rural , Índice de Severidad de la Enfermedad , Distribución por Sexo , Factores Socioeconómicos , Población UrbanaRESUMEN
Abstract The authors present a proposal of a partnership between the Sociedade Brasileira de Oncologia Pediátrica (SOBOPE) and the International Society of Pediatric Oncology (SIOP) to promote the standardization and improvement of nutritional care of kids under cancer treatment in Brazil. The results of the first meeting in Brazil as well as plans for future meetings are described.
Asunto(s)
Pediatría , Pobreza , Brasil , Niño , Enfermedades Carenciales , Nutrición del Niño , Oncología MédicaRESUMEN
ABSTRACT Background: Acute myeloid leukemia presenting the MYST3-CREBBP fusion gene is a rare subgroup associated with hemophagocytosis in early infancy and monocytic differentiation. The aim of this study was to define the relevant molecular cytogenetic characteristics of a unique series of early infancy acute myeloid leukemia cases (≤24 months old), based on the presence of hemophagocytosis by blast cells at diagnosis. Methods: A series of 266 infant cases of acute myeloid leukemia was the reference cohort for the present analysis. Acute myeloid leukemia cases with hemophagocytosis by blast cells were reviewed to investigate the presence of the MYST3-CREBBP fusion gene by fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction. Results: Eleven cases with hemophagocytosis were identified with hemophagocytic lymphohistiocytosis being ruled out. Six cases were classified as myelomonocytic leukemia, three as AML-M7 and two as AML-M2. In five cases, the presence of the MYST3-CREBBP fusion gene identified by molecular cytogenetics was confirmed by fluorescence in situ hybridization. All patients received treatment according to the Berlin-Frankfürt-Münster acute myeloid leukemia protocols and only one out of the five patients with the MYST3-CREBBP fusion gene is still alive. Conclusions: Our findings demonstrate that the presence of hemophagocytosis in acute myeloid leukemia was not exclusively associated to the MYST3-CREBBP fusion gene. Improvements in molecular cytogenetics may help to elucidate more complex chromosomal rearrangements in infants with acute myeloid leukemia and hemophagocytosis.
Asunto(s)
Fagocitosis , Leucemia Mieloide Aguda , Niño , Intrones/genética , Quimera/genética , Elementos Alu/genéticaRESUMEN
A anemia aplástica severa é uma doença rara que acomete pessoas de todas as regiöes do mundo. Devido a sua raridade, existem dificuldades em se caracterizar o perfil dos pacientes acometidos pela doença, assim como identificar possíveis fatores implicados na sua etiologia. OBJETIVO: Descrever o perfil dos pacientes pediátricos atendidos com anemia aplástica severa, analisando variáveis como distribuiçäo de idade, sexo, local de habitaçäo, etiologia e nível socioeconômico. MÉTODOS: FOI realizada uma análise descritiva das características encontradas em todos os pacientes com idade inferior a 18 anos, encaminhados no período de 1979-1993 com diagnóstico da doença, conforme classificaçäo proposta por Camitta et al. As informaçöes foram obtidas através do prontuário médico e de um questionário aplicado pela pesquisadora em 79 das 134 famílias. RESULTADOS: A média das idades foi de 10,89 anos. Houve leve predominância do sexo feminino. A maioria dos pacientes residia na zona urbana da regiäo sul do país. 34 por cento das famílias näo identificaram um fator causal. Os pesticidas agrícolas e os derivados de benzeno foram os fatores causais mais relatados no questionário. Das 79 famílias que responderam ao questionário, 83,5 por cento tinham renda familiar inferior a 1 salário mínimo " per capita" e 70,9 por cento das mäes tinham nível de escolaridade inferior o primeiro grau completo. CONCLUSÄO: O perfil da populaçäo pediátrica com anemia aplástica severa atendida no Serviço de Transplante de Medula Ossea de Curitiba é formado predominantemente por crianças de 11 anos, do sexo feminino, provenientes da zona urbana da regiäo sul do país, com baixo nível socioeconômico, que relataram os pesticidas agrícolas e derivados de benzeno como possíveis fatores etiológicos